EU green light to IntraBio’s AQNEURSA for rare neurological disease Niemann-Pick Type C
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
Subscribe To Our Newsletter & Stay Updated